Updated on 17 February 2014
Owing to Irinotecan's steady growth in the Japanese market and Gemcitabine for the treatment of non-small-cell lung cancer that entered mass production, ScinoPharm has doubled its sales performance in the Japanese market. The company opened an office in Tokyo in July of last year to more effectively capture a part of Japan's emerging generics market.
ScinoPharm has developed nearly 70 products, 23 of which have been launched in the market. By 2014, seven additional API items are expected to be launched in the US, Canadian, European and Japanese markets. These include oncology drugs and drugs for MDS, anti-neoplastic, HBV, malignant hyperthermia, osteoporosis and other indications.